137 related articles for article (PubMed ID: 30777332)
21. Genomic Signature of the Standardized Uptake Value in
Kim SK; Ahn SG; Mun JY; Jeong MS; Bae SJ; Lee JS; Jeong J; Leem SH; Chu IS
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093417
[TBL] [Abstract][Full Text] [Related]
22. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Analysis of (18)F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Cui Y; Song J; Pollom E; Alagappan M; Shirato H; Chang DT; Koong AC; Li R
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):102-9. PubMed ID: 27511850
[TBL] [Abstract][Full Text] [Related]
24. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
Karan B; Pourbagher A; Torun N
J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
[TBL] [Abstract][Full Text] [Related]
25. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
Morris PG; Ulaner GA; Eaton A; Fazio M; Jhaveri K; Patil S; Evangelista L; Park JY; Serna-Tamayo C; Howard J; Larson S; Hudis CA; McArthur HL; Jochelson MS
Cancer; 2012 Nov; 118(22):5454-62. PubMed ID: 22517371
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
27. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
28. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
[TBL] [Abstract][Full Text] [Related]
30. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
32. Cancer-associated fibroblasts enhance tumor
Shangguan C; Gan G; Zhang J; Wu J; Miao Y; Zhang M; Li B; Mi J
Theranostics; 2018; 8(5):1376-1388. PubMed ID: 29507627
[No Abstract] [Full Text] [Related]
33. Radiogenomic Analysis Demonstrates Associations between (18)F-Fluoro-2-Deoxyglucose PET, Prognosis, and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.
Yamamoto S; Huang D; Du L; Korn RL; Jamshidi N; Burnette BL; Kuo MD
Radiology; 2016 Jul; 280(1):261-70. PubMed ID: 27082783
[TBL] [Abstract][Full Text] [Related]
34.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
35. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
36. The clinical significance of standardized uptake value in breast cancer measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Kim YH; Lee JA; Baek JM; Sung GY; Lee DS; Won JM
Nucl Med Commun; 2015 Aug; 36(8):790-4. PubMed ID: 25932535
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
38. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
[TBL] [Abstract][Full Text] [Related]
39. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
40. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
